Menu
Share this

Hematology and Oncology Expertise


With more than 2,100 hematology and oncology trained staff, PPD provides our clients with dedicated internal resources throughout their studies. Some of our key experts and their insights are highlighted below.

Her leadership includes managing a team of directors, associate directors and project managers who are accountable for all project deliverables.

Donnelly joined PPD in 1995 as a clinical research associate (CRA) after a similar role with American Cyanamid in Great Britain. While at PPD, she served as project manager for several large registrational trials before leaving the company in 2001 for additional industry experience. She joined Bristol Myers-Squibb as a clinical protocol manager and spent 13 years honing her therapeutic area and leadership expertise through a series of positions with increased levels of responsibility across in-house and outsourced programs and teams. While her therapeutic expertise is greatest in hematology and oncology, she also has clinical research experience in the areas of infectious disease, immunoscience, metabolics and neurology.

Donnelly holds a bachelor’s degree in pharmacology from University College Dublin in Ireland, and a Master of Business Administration from the University of North Carolina Wilmington.

White Papers

White Paper: Adaptive Trial Designs to Advance Oncology Research

Adaptive trial designs offer the means to make oncology trials more informative and efficient.

White Paper: Advancing Early Phase Oncology Trials in the Era of Targeted Medicine

PPD experts discuss applications of translational research to improve the likelihood of success in later phase development.

Hematology and Oncology experience infographic

leads the company’s biosimilar services development group, which brings together cross-functional, global expertise and resources in the development of large molecule biologic drugs.

Dr. Reitsma has extensive clinical development experience, having joined PPD in 2010 from MedImmune, where he served as vice president of clinical development since 2004. At MedImmune, he led the company’s active clinical oncology programs in biologics, and oversaw the expansion of its oncology clinical development department. Dr. Reitsma’s experience also includes serving as vice president of clinical affairs and medical director at Antigenics, and as associate director and senior clinical research physician in oncology at Novartis Pharmaceuticals.

Earlier in his career, he was associate director, clinical research head, clinical section, at Bionetics Research, Inc., and medical advisor in the medical research department at Organon International, Inc. in Rotterdam, The Netherlands. Dr. Reitsma received a bachelor’s degree in science from the Medical Faculty of Rotterdam and a medical degree from Erasmus University in The Netherlands.

Case Study

Case Study: Pediatric Leukemia

PPD was selected to conduct central study activities for a Phase I/II pediatric leukemia study that evaluated study drug.

director of PPD’s biosimilar development services group and the rare disease, pediatric and collaborative trials working groups.

Dr. Healey has more than 10 years of pre-approval and post-approval pharmaceutical industry and drug development experience. He joined PPD in 2004 as operations supervisor of medical communications and has assumed leadership positions of increasing responsibility, culminating in the promotion to his current position in 2014. His prior employment included serving as a relief pharmacist with Harris Teeter, a sales representative with Eli Lilly & Company and an adjunct professor at Campbell University. His therapeutic experience includes musculoskeletal, nervous system, endocrine, genitourinary, pain management, oncology, digestive, circulatory and mental disorders.

Dr. Healey received a bachelor’s degree in biology from St. Lawrence University. At Campbell University he earned a master’s degree in business administration, a doctorate in pharmacy and a master’s degree in clinical research.


Additional Hemotology/Oncology Resources

With more than 2,100 hematology and oncology trained staff, PPD provides our clients with dedicated internal resources throughout their studies. Some of our key experts and their insights are highlighted below.

Alice Donnelly

Vice President, Hematology and Oncology, Global Project Management

Alice Donnelly is vice president and therapeutic area head for global project management.
Carol Woodward

In this role, she serves as global therapeutic head with overall global responsibility for the strategic direction, business operations and operational delivery for all hematology and oncology studies.

Her leadership includes managing a team of directors, associate directors and project managers who are accountable for all project deliverables.

Donnelly joined PPD in 1995 as a clinical research associate (CRA) after a similar role with American Cyanamid in Great Britain. While at PPD, she served as project manager for two registrational trials in HIV/AIDS before leaving the company in 2001 for additional industry experience. She joined Bristol Myers-Squibb as a clinical protocol manager and spent 13 years honing her therapeutic area and leadership expertise through a series of positions with increased levels of responsibility across in-house and outsourced programs and teams. While her therapeutic expertise is greatest in hematology and oncology, she also has clinical research experience in the areas of infectious disease, immunoscience, metabolics and neurology.

Donnelly holds a bachelor’s degree in pharmacology from University College Dublin in Ireland, and a Master of Business Administration from the University of North Carolina Wilmington.

White Paper

White Paper: Adaptive Trial Designs to Advance Oncology Research

Adaptive trial designs offer the means to make oncology trials more informative and efficient.

Dirk Reitsma, M.D.

Vice President, Global Product Development

Dirk Reitsma, M.D., is vice president and oncology therapeutic area head for global product development.
Dirk Reitsma, M.D.

In this role, he leads the oncology product development strategy team and provides clinical trial design guidance to clients in this therapeutic category. In addition, he established and leads the company’s biosimilar services development group, which brings together cross-functional, global expertise and resources in the development of large molecule biologic drugs.

Dr. Reitsma has extensive clinical development experience, having joined PPD in 2010 from MedImmune, where he served as vice president of clinical development since 2004. At MedImmune, he led the company’s active clinical oncology programs in biologics, and oversaw the expansion of its oncology clinical development department. Dr. Reitsma’s experience also includes serving as vice president of clinical affairs and medical director at Antigenics, and as associate director and senior clinical research physician in oncology at Novartis Pharmaceuticals.

Earlier in his career, he was associate director, clinical research head, clinical section, at Bionetics Research, Inc., and medical advisor in the medical research department at Organon International, Inc. in Rotterdam, The Netherlands. Dr. Reitsma received a bachelor’s degree in science from the Medical Faculty of Rotterdam and a medical degree from Erasmus University in The Netherlands.

Case Study

Case Study: Pediatric Leukemia

PPD was selected to conduct central study activities for a Phase I/II pediatric leukemia study that evaluated study drug.

Brian Healey, Pharm.D

Associate Director, PPD Consulting

As associate director of PPD Consulting, Brian Healey provides biopharmaceutical clients with strategic development consulting and comprehensive program management.
Brian Healey

He designs and executes drug development plans from early preclinical/pre-IND planning through NDA submission. Operationally, he establishes and monitors budgets and timelines to ensure development program milestones are achieved on time and within budget.

He also supports business development activities by providing competitive landscape analyses for therapeutically aligned development groups across major indications and medicinal targets. He is the client’s primary point of contact regarding all aspects of the development program, ensuring development team activities are aligned with client and corporate objectives.

Dr. Healey joined PPD in 2004 as operations supervisor of medical communications. He was named manager of global product development in 2006 and promoted to his current position in 2011. His prior employment included serving as a relief pharmacist with Harris Teeter, a sales representative with Eli Lilly & Company and an adjunct professor at Campbell University. His therapeutic experience includes musculoskeletal, nervous system, endocrine, genitourinary, pain management, oncology, digestive, circulatory and mental disorders.

Dr. Healey received a bachelor’s degree in biology from St. Lawrence University. At Campbell University he earned a master’s degree in business administration, a doctorate in pharmacy and a master’s degree in clinical research.

Contact Site Map Legal Notices Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.

Google+